Regorafenib in the treatment of malignant tumor / 国际肿瘤学杂志
Journal of International Oncology
; (12): 191-192,231, 2013.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-598211
Biblioteca responsável:
WPRO
ABSTRACT
Regorafenib,an oral multi-kinase inhibitor,can inhabit a class of receptor tyrosine kinase,such as angiogenic,stromal,oncogenic and so on.Studies in vitro and clinical trials indicate that Regorafenib has significant antitumor activity.The results of clinical trials are encouraging for the treatment of Refractory solid tumors,especially for colorectal carcinoma.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of International Oncology
Ano de publicação:
2013
Tipo de documento:
Artigo